Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to: Hippo signalling maintains ER expression and ER+ breast cancer growth

The Original Article was published on 03 March 2021

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Ma, S. et al. Hippo signalling maintains ER expression and ER+ breast cancer growth. Nature, https://doi.org/10.1038/s41586-020-03131-5 (2021).

  2. 2.

    Britschgi, A. et al. The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα. Nature 541, 541–545 (2017).

    ADS  CAS  Article  Google Scholar 

  3. 3.

    Zhao, B., Li, L., Tumaneng, K., Wang, C. Y. & Guan, K. L. A coordinated phosphorylation by LATS and CK1 regulates YAP stability through SCFβ-TRCP. Genes Dev. 24, 72–85 (2010).

    CAS  Article  Google Scholar 

  4. 4.

    Totaro, A., Panciera, T. & Piccolo, S. YAP/TAZ upstream signals and downstream responses. Nat. Cell Biol. 20, 888–899 (2018).

    CAS  Article  Google Scholar 

  5. 5.

    Rossi, A. et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature 524, 230–233 (2015).

    ADS  CAS  Article  Google Scholar 

  6. 6.

    Duss, S. et al. Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells. Breast Cancer Res. 16, R60 (2014).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

A.B., J.P.C. and M.B.-A. wrote the response. The author list for this Reply differs from the author list of the original Article to accelerate the response to the Comment.

Corresponding author

Correspondence to Mohamed Bentires-Alj.

Ethics declarations

Competing interests

A.B. is an employee of Roche Pharma AG and J.P.C. of Novartis. M.B.-A. and A.B. are inventors on the US patent WO2016046768A1 ‘Lats and breast cancer’.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Britschgi, A., Couto, J.P. & Bentires-Alj, M. Reply to: Hippo signalling maintains ER expression and ER+ breast cancer growth. Nature 591, E11–E12 (2021). https://doi.org/10.1038/s41586-020-03132-4

Download citation

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing